Cancer clinical trials in the region Provence-Alpes-Côte d'Azur
436 currently recruiting clinical trials
Looking for clinical trials?
Clinical trial search is a complex process, with countless criteria to consider. Our AI assistant navigates this complexity with precise, expert-level analysis of the most relevant trials based on your medical profile. Our database is fully up to date, so you see only actively recruiting sites. It's fast and easy:
- Create your account
- Copy-paste your latest medical report
- Our AI-based assistant does the rest for you
Whether you are a patient or a doctor, create an account to find and apply for the most relevant clinical trials:
Phase 1 / Phase 2
Acute leukemia
#NCT04811560
Phase 1
Required central nervous system lesions
None
Treated / Controled
Required genetic anomalies
Other mutation
KMT2A
NPM1
NUP214
Required number of previous lines of therapy
1
2
3 or more
Excluded previous treatments
Systemic Treatment-Naive
11 recruiting sites
Janssen
Phase 1 / Phase 2
Head and neck cancer
#NCT06385080
#2023-508418-40-00
Cohorte 4 Carcinome épidermoïde de la tête et du cou récidivant/métastatique
Required histologic types
Oropharynx
Required histologic sub types
Squamous cell carcinoma
Required disease stage
Locally Advanced
Metastatic
Required number of previous lines of therapy for current stage of disease
1
2
3 or more
Required P16 statuses
P16 Positive
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
5 recruiting sites
Janssen
Phase 1 / Phase 2
Head and neck cancer
#NCT06385080
#2023-508418-40-00
Cohorte 5 Carcinome épidermoïde de la tête et du cou récidivant/métastatique
Required histologic types
Oral cavity
Oropharynx
Hypopharynx
Larynx
Required histologic sub types
Squamous cell carcinoma
Required disease stage
Locally Advanced
Metastatic
Required number of previous lines of therapy for current stage of disease
1
2
3 or more
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
5 recruiting sites
Janssen
Phase 1 / Phase 2
Head and neck cancer
#NCT06385080
#2023-508418-40-00
Cohorte 6 Carcinome épidermoïde de la tête et du cou localement avancé
Required histologic types
Oral cavity
Oropharynx
Hypopharynx
Larynx
Required histologic sub types
Squamous cell carcinoma
Required disease stage
Localized
Locally Advanced
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at localized stage
Systemic Treatment-Naive
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Required P16 statuses
P16 Negative
5 recruiting sites
Janssen
Phase 1 / Phase 2
Acute leukemia
#NCT04988555
[Horizen-1 Étude de phase 1/2 de l'Enzomenib (DSP-5336) chez les patients atteints de leucémie aiguë
Phase 1, Bras L, M et N
Required histologic types
Acute myeloid leukemia (AML)
Required central nervous system lesions
None
Treated / Controled
Required renal function statuses
> 60 ml/min
50-60 ml/min
Required genetic anomalies
KMT2A
NPM1
Required number of previous lines of therapy
None
Required previous treatments
Systemic Treatment-Naive
8 recruiting sites
Sumitomo Pharma America, Inc.
Phase 1 / Phase 2
Acute leukemia
#NCT04988555
#2022-502741-10-00
Phase 2, Bras G, H et K
Required histologic types
Acute myeloid leukemia (AML)
Required central nervous system lesions
None
Treated / Controled
Required renal function statuses
> 60 ml/min
50-60 ml/min
Required genetic anomalies
MLL fusions
NPM1
Required number of previous lines of therapy
1
2
3 or more
Excluded previous treatments
Systemic Treatment-Naive
8 recruiting sites
Sumitomo Pharma America, Inc.
Phase 1 / Phase 2
Acute leukemia
#NCT04988555
Phase 2, bras J
Required genetic anomalies
MLL fusions
Required number of previous lines of therapy
1
2
3 or more
Excluded previous treatments
Systemic Treatment-Naive
8 recruiting sites
Sumitomo Pharma America, Inc.
Phase 1 / Phase 2
Acute leukemia
#NCT04988555
#2022-502741-10-00
Phase 2 - Bras I
Required histologic types
Acute lymphoblastic leukemia (ALL)
Required central nervous system lesions
None
Required renal function statuses
> 60 ml/min
50-60 ml/min
Required genetic anomalies
KMT2A
Required number of previous lines of therapy
1
2
3 or more
8 recruiting sites
Sumitomo Pharma America, Inc.
Phase 1 / Phase 2
Lung cancer
Bladder / Urinary Tract / Urethral cancer
Stomach and esophageal cancer
Head and neck cancer
#NCT06923761
#2023-504845-30-00
Module 2 Cohorte 3 Tumeurs solides avec un TMB médian modéré à élevé
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Stomach
Oesogastric junction
Esophagus
Invasive bladder cancer
Oral cavity
Nasopharynx
Oropharynx
Hypopharynx
Larynx
Nasal cavities and sinuses
Required histologic sub types
Adenocarcinoma
Squamous cell carcinoma
Urothelial carcinoma
Required disease stage
Locally Advanced
Metastatic
Required number of previous lines of therapy for current stage of disease
1
2
Required previous treatments at advanced or metastatic stage
Immunotherapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
7 recruiting sites
Grey Wolf Therapeutics
Phase 1 / Phase 2
Acute leukemia
#NCT05768035
Required histologic types
Acute lymphoblastic leukemia (ALL)
Acute myeloid leukemia (AML)
Required number of previous lines of therapy
1
2
3 or more
Excluded previous treatments
Systemic Treatment-Naive
Allogeneic stem cell transplant
4 recruiting sites
Smart Immune SAS